Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 8/20 | 0.68 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19090245 | 1.00 | SMYD3 (0.68) | SMYD3DPP4SOS1MEN1KMT2A | |
| SCHEMBL19090248 | 0.89 | SMYD3 (0.67) | SMYD3DPP4SOS1MEN1KMT2A | |
| SCHEMBL19090244 | 0.89 | SMYD3 (0.67) | SMYD3DPP4SOS1MEN1KMT2A | |
| SCHEMBL19079334 | 0.86 | SMYD3 (0.80) | SMYD3DPP4SOS1MEN1KMT2A | |
| SCHEMBL19079348 | 0.86 | SMYD3 (0.80) | SMYD3DPP4SOS1MEN1KMT2A | |
| SCHEMBL19734019 | 0.81 | SMYD3 (1.00) | SMYD3SOS1KRAS | |
| SCHEMBL19079333 | 0.80 | SMYD3 (0.78) | SMYD3DPP4MEN1KMT2AAKT1 | |
| SCHEMBL19079347 | 0.80 | SMYD3 (0.78) | SMYD3DPP4MEN1KMT2AAKT1 | |
| SCHEMBL19079332 | 0.79 | SMYD3 (0.76) | SMYD3DPP4SOS1MEN1KMT2A | |
| SCHEMBL19079337 | 0.79 | SMYD3 (0.76) | SMYD3DPP4SOS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428029-B2 | Isoxazole carboxamide compounds | Epizyme, Inc. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | Epizyme, Inc. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428029-B2 | Isoxazole carboxamide compounds | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885DPP4 3140/4885SOS1 2324/4885 |
| US-20170190676-A1 | Isoxazole Carboxamide Compounds | SMYD3, SMYD2, SNRPD3 | SMYD3 1/4885DPP4 3140/4885SOS1 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.